Analyze Diet

Topic:Regenerative Medicine

Regenerative medicine in horses involves the use of biological therapies to repair or replace damaged tissues and organs. This field focuses on enhancing the body's natural healing processes through the application of stem cells, platelet-rich plasma (PRP), and other bioactive substances. These therapies aim to improve the recovery of musculoskeletal injuries, such as tendon and ligament damage, which are common in equine athletes. Research in regenerative medicine explores the mechanisms of tissue regeneration, the efficacy of different treatment modalities, and their application in clinical settings. This page aggregates peer-reviewed research studies and scholarly articles that investigate the methodologies, outcomes, and potential applications of regenerative medicine in equine veterinary practice.
Tendon regeneration in human and equine athletes: Ubi Sumus-Quo Vadimus (where are we and where are we going to)?
Sports medicine (Auckland, N.Z.)    September 12, 2012   Volume 42, Issue 10 871-890 doi: 10.1007/BF03262300
Spaas JH, Guest DJ, Van de Walle GR.Tendon injuries are one of the most common orthopaedic problems in both human and equine athletes. When a damaged tendon heals naturally, it loses a substantial part of the original strength and elasticity. Therefore, tendons recover structurally (reparation) but not functionally (regeneration) after conservative medical or surgical treatment. Since the structure and matrix composition of human and equine tendons share many similarities, the nature of tendon injuries are also strongly comparable in both species. Therefore, the evaluation of regenerative therapies in horses may have application...
Ovine amniotic epithelial cells: in vitro characterization and transplantation into equine superficial digital flexor tendon spontaneous defects.
Research in veterinary science    September 3, 2012   Volume 94, Issue 1 158-169 doi: 10.1016/j.rvsc.2012.07.028
Muttini A, Valbonetti L, Abate M, Colosimo A, Curini V, Mauro A, Berardinelli P, Russo V, Cocciolone D, Marchisio M, Mattioli M, Tosi U....In vitro expanded and frosted ovine amniotic epithelial cells (oAECs) were evaluated for their phenotype, stemness and attitude to differentiate into tenocytes. Fifteen horses with acute tendon lesions were treated with one intralesional injection of oAECs. Tendon recovery under controlled training was monitored. In vitro expanded oAECs showed a constant proliferative ability, a conserved phenotype and stable expression profile of stemness markers. Differentiation into tenocytes was also regularly documented. US controls showed the infilling of the defect and early good alignment of the fibers...
Making progress in the what, when and where of regenerative medicine for our equine patients.
Equine veterinary journal    August 15, 2012   Volume 44, Issue 5 511-512 doi: 10.1111/j.2042-3306.2012.00628.x
Fortier LA.No abstract available
Erratum: Novel nanostructured scaffold for osteochondral regeneration: pilot study in horses.
Journal of tissue engineering and regenerative medicine    February 2, 2012   Volume 10, Issue 12 981 doi: 10.1002/term.1473
Kon E, Muttini A, Arcangeli E, Delcogliano M, Filardo G, Nicoli Aldini N, Pressato D, Quarto R, Zaffagnini S, Marcacci M.No abstract available
[Regenerative therapy for tendon and ligament disorders in horses. Terminology, production, biologic potential and in vitro effects].
Tierarztliche Praxis. Ausgabe G, Grosstiere/Nutztiere    December 15, 2011   Volume 39, Issue 6 373-383 
Geburek F, Stadler P.Conventional treatments of equine tendon injuries lead to an unsatisfactory healing process that usually results in a relatively high recurrence rate. Therefore, in recent years so-called regenerative therapeutics were studied scientifically in vitro and in laboratory animals. These include substances that ideally lead to the formation of replacement tissue, which in contrast to the low quality scar, has similar functional properties as the original intact tendon. Currently, a plethora of different substrates is either commercially available or can be produced in practice with the help of kits...
Characterization and differentiation of equine tendon-derived progenitor cells.
Journal of biological regulators and homeostatic agents    December 8, 2011   Volume 25, Issue 2 Suppl S75-S84 
Lovati AB, Corradetti B, Lange Consiglio A, Recordati C, Bonacina E, Bizzaro D, Cremonesi F.Mesenchymal stem cells have been recently investigated for their potential use in regenerative medicine. Population of adult stem cells were recently identified in human and lab animal tendons, but no detailed investigations have been made in the equine species. The aim of our study is to identify a progenitor cell population from tendon tissue (TSPCs) in the horse superficial digital flexor tendon that are able to be highly clonogenic, to grow fast and to differentiate in different induced cell lineages as well as bone marrow derived progenitor cells (BM-MSCs). The hypothesis that TSPCs posse...
The combination of purified recombinant human platelet-derived growth factor-BB and equine particulate bone graft for periodontal regeneration.
Journal of periodontology    October 20, 2011   Volume 83, Issue 5 565-573 doi: 10.1902/jop.2011.110298
Nevins M, Nevins ML, Karimbux N, Kim SW, Schupbach P, Kim DM.The objective of this study is to evaluate the potential for periodontal regeneration of a critical-sized defect with the application of recombinant human platelet-derived growth factor (rhPDGF-BB) combined with either a particulate equine or a β-tricalcium phosphate (β-TCP) matrix. Methods: Critical-sized intrabony 2-wall defects were created bilaterally on the distal surface of the second premolar and the mesial surface of the first molar in nine hounds. Twelve defects received rhPDGF-BB/equine treatment, 12 defects received rhPDGF-BB/β-TCP treatment, and the remaining 12 sites served as ...
Comments on Torricelli et al.: regenerative medicine for the treatment of musculoskeletal overuse injuries in competition horses.
International orthopaedics    September 13, 2011   Volume 35, Issue 11 1745-1748 doi: 10.1007/s00264-011-1311-x
Carmona JU, López C.No abstract available
Isolation and characterization of equine amnion mesenchymal stem cells.
Cell biology international reports    September 13, 2011   Volume 18, Issue 1 e00011 doi: 10.1042/CBR20110004
Coli A, Nocchi F, Lamanna R, Iorio M, Lapi S, Urciuoli P, Scatena F, Giannessi E, Stornelli MR, Passeri S.The amnion is a particular tissue whose cells show features of multipotent stem cells proposed for use in cellular therapy and regenerative medicine. From equine amnion collected after the foal birth we have isolated MSCs (mesenchymal stem cells), namely EAMSCs (equine amnion mesenchymal stem cells), from the mesoblastic layer. The cells were grown in α-MEM (α-modified minimum essential medium) and the effect of EGF (epidermal growth factor) supplementation was evaluated. To assess the growth kinetic of EAMSCs we have taken into account some parameters [PD (population doubling), fold increas...
Cell-based therapies for tendon and ligament injuries.
The Veterinary clinics of North America. Equine practice    August 30, 2011   Volume 27, Issue 2 315-333 doi: 10.1016/j.cveq.2011.06.001
Alves AG, Stewart AA, Dudhia J, Kasashima Y, Goodship AE, Smith RK.Tendon and ligament injuries have proved difficult to treat effectively. Cell-based therapies offer the potential to harness the complex protein synthetic machinery of the cell to induce a regenerative response rather than fibrous scarring. This article reviews the current state of play with respect to the clinically used cell preparations for the treatment of tendon and ligaments overstrain injuries.
Collection and propagation methods for mesenchymal stromal cells.
The Veterinary clinics of North America. Equine practice    August 30, 2011   Volume 27, Issue 2 263-274 doi: 10.1016/j.cveq.2011.05.003
Taylor SE, Clegg PD.Mesenchymal stromal cells (MSC) are derived from adult mesenchymal tissues and have the ability to undergo differentiation into bone, cartilage, and fat, and have therefore attracted great interest in regenerative medicine. Many isolation and culture methods have been described, making comparison between laboratories and quality-control protocols difficult. A uniform protocol to characterize equine MSC has recently been proposed, aiming to introduce consistency across the equine stem cell research field. This article reviews the published techniques for collection and propagation of equine MSC...
Cell-based therapies: current issues and future directions.
The Veterinary clinics of North America. Equine practice    August 30, 2011   Volume 27, Issue 2 393-399 doi: 10.1016/j.cveq.2011.07.001
Stewart MC.This article focuses on current issues facing cell-based therapies in equine practice and future studies validating the use of stem cells and related biologic therapies for the treatment of musculoskeletal conditions in the horse. Issues raised include the characterization and use of tissue- and anatomic location-specific mesenchymal stem cell (MSC) sources, the putative advantages and feasibility of allogeneic embryonic stem cell and MSC products, the technical advantages and performance of cell-based biologic agents that do not require extensive ex vivo manipulation, the regulation of MSC ho...
Characterization of adipose-derived equine and canine mesenchymal stem cells after incubation in agarose-hydrogel.
Veterinary research communications    July 15, 2011   Volume 35, Issue 8 487-499 doi: 10.1007/s11259-011-9492-8
Schwarz C, Leicht U, Drosse I, Ulrich V, Luibl V, Schieker M, Röcken M.Adult stem cells are of particular interest for the therapeutic approach in the field of regenerative medicine. Due to their ease of harvest, adipose-derived mesenchymal stem cells (ASCs) are an attractive stem cell source that has become increasingly popular. Critical aspects of applied cell therapies are the circumstances of transport from the laboratory towards the site of operation and cell delivery into the desired area. With regard to these issues, agarose-hydrogel was analyzed as a cell carrier matrix of equine and canine ASCs in vitro, which can be used for minimally invasive applicati...
Further insights into the characterization of equine adipose tissue-derived mesenchymal stem cells.
Veterinary research communications    May 26, 2011   Volume 35, Issue 6 355-365 doi: 10.1007/s11259-011-9480-z
Raabe O, Shell K, Würtz A, Reich CM, Wenisch S, Arnhold S.Adipose tissue-derived stem cells (ADSCs) represent a promising subpopulation of adult stem cells for tissue engineering applications in veterinary medicine. In this study we focused on the morphological and molecular biological properties of the ADSCs. The expression of stem cell markers Oct4, Nanog and the surface markers CD90 and CD105 were detected using RT-PCR. ADSCs showed a proliferative potential and were capable of adipogenic and osteogenic differentiation. Expression of Alkaline phosphatase (AP), phosphoprotein (SPP1), Runx2 and osteocalcin (OC) mRNA were positive in osteogenic linea...
Evaluation of senescence in mesenchymal stem cells isolated from equine bone marrow, adipose tissue, and umbilical cord tissue.
Stem cells and development    May 6, 2011   Volume 21, Issue 2 273-283 doi: 10.1089/scd.2010.0589
Vidal MA, Walker NJ, Napoli E, Borjesson DL.Mesenchymal stem cells (MSCs) from adult and neonatal tissues are intensively investigated for their use in regenerative medicine. The purpose of this study was to compare the onset of replicative senescence in MSCs isolated from equine bone marrow (BMSC), adipose tissue (ASC), and umbilical cord tissue (UCMSC). MSC proliferation (cell doubling), senescence-associated β-galactosidase staining, telomere length, Sox-2, and lineage-specific marker expression were assessed for MSCs harvested from tissues of 4 different donors. The results show that before senescence ensued, all cell types prolife...
Regenerative medicine for the treatment of musculoskeletal overuse injuries in competition horses.
International orthopaedics    March 11, 2011   Volume 35, Issue 10 1569-1576 doi: 10.1007/s00264-011-1237-3
Torricelli P, Fini M, Filardo G, Tschon M, Pischedda M, Pacorini A, Kon E, Giardino R.Tissue repair in musculoskeletal injuries is often a slow and sometimes incomplete process. Regenerative medicine based on the use of growth factors (GFs) and cell therapy is aimed at improving the quality and speed of tendon and ligament healing. The aim of this study was to evaluate the potential for the administration of a combination of autologous platelet-rich plasma (PRP) and freshly isolated bone marrow mononucleated cells (BMMNCs) in 13 competition horses affected by overuse musculoskeletal injuries (suspensory ligament desmopathy and superficial flexor tendinopathy) and refractory to ...
Induced pluripotent stem cell lines derived from equine fibroblasts.
Stem cell reviews and reports    February 25, 2011   Volume 7, Issue 3 693-702 doi: 10.1007/s12015-011-9239-5
Nagy K, Sung HK, Zhang P, Laflamme S, Vincent P, Agha-Mohammadi S, Woltjen K, Monetti C, Michael IP, Smith LC, Nagy A.The domesticated horse represents substantial value for the related sports and recreational fields, and holds enormous potential as a model for a range of medical conditions commonly found in humans. Most notable of these are injuries to muscles, tendons, ligaments and joints. Induced pluripotent stem (iPS) cells have sparked tremendous hopes for future regenerative therapies of conditions that today are not possible to cure. Equine iPS (EiPS) cells, in addition to bringing promises to the veterinary field, open up the opportunity to utilize horses for the validation of stem cell based therapi...
The regenerative medicine laboratory: facilitating stem cell therapy for equine disease.
Clinics in laboratory medicine    February 8, 2011   Volume 31, Issue 1 109-123 doi: 10.1016/j.cll.2010.12.001
Borjesson DL, Peroni JF.This article focuses on the emerging field of equine regenerative medicine with an emphasis on the use of mesenchymal stem cells (MSCs) for orthopedic diseases. We detail laboratory procedures and protocols for tissue handling and MSC isolation, characterization, expansion, and cryopreservation from bone marrow, fat, and placental tissues. We provide an overview of current clinical uses for equine MSCs and how MSCs function to heal tissues. Current laboratory practices in equine regenerative medicine mirror those in the human field. However, the translational use of autologous and allogeneic M...
Evaluation of the osteogenic and chondrogenic differentiation capacities of equine adipose tissue-derived mesenchymal stem cells.
American journal of veterinary research    October 6, 2010   Volume 71, Issue 10 1228-1236 doi: 10.2460/ajvr.71.10.1228
Braun J, Hack A, Weis-Klemm M, Conrad S, Treml S, Kohler K, Walliser U, Skutella T, Aicher WK.To evaluate the proliferative behavior, telomere length, immunophenotype, and differentiation capacity of equine adipose tissue-derived mesenchymal stem cells (AT-MSCs). Methods: 6 adult racing horses treated for articular Injury but otherwise healthy. Methods: AT-MSCs were Isolated from horses and expanded In Dulbecco modified Eagle medium enriched with fetal bovine serum and antimicrobials. Expression of cell surface antigens and telomere length were Investigated via flow cytometry Differentiation of MSCs Into chondrocytes, osteoblasts, and adipocytes was Induced In vitro by specific stimuli...
Release kinetics of VEGF165 from a collagen matrix and structural matrix changes in a circulation model.
Head & face medicine    July 19, 2010   Volume 6 17 doi: 10.1186/1746-160X-6-17
Kleinheinz J, Jung S, Wermker K, Fischer C, Joos U.Current approaches in bone regeneration combine osteoconductive scaffolds with bioactive cytokines like BMP or VEGF. The idea of our in-vitro trial was to apply VEGF165 in gradient concentrations to an equine collagen carrier and to study pharmacological and morphological characteristics of the complex in a circulation model. Methods: Release kinetics of VEGF165 complexed in different quantities in a collagen matrix were determined in a circulation model by quantifying protein concentration with ELISA over a period of 5 days. The structural changes of the collagen matrix were assessed with lig...
Comparative efficacy of dermal fibroblast-mediated and direct adenoviral bone morphogenetic protein-2 gene therapy for bone regeneration in an equine rib model.
Gene therapy    March 11, 2010   Volume 17, Issue 6 733-744 doi: 10.1038/gt.2010.13
Ishihara A, Zekas LJ, Weisbrode SE, Bertone AL.Cell-mediated and direct adenoviral (Ad) vector gene therapies can induce bone regeneration, including dermal fibroblasts (DFbs). We compared two effective therapies, DFb-mediated and direct Ad vector delivery of bone morphogenetic protein-2 (BMP2), for relative efficacy in bone regeneration. Equine rib drill defects were treated by percutaneous injection of either DFb-BMP2 or an Ad-BMP2 vector. At week 6, both DFb-BMP2- and Ad-BMP2-treated rib defects had greater bone filling volume and mineral density, with DFb-BMP2 inducing greater bone volume and maturity in the cortical bone aspect of the...
‘Can you regain your youth?’–the real potential of stem cell technology.
Equine veterinary journal    February 4, 2010   Volume 42, Issue 1 2-4 doi: 10.2746/042516409X474392
Smith RK.No abstract available
Current and future regenerative medicine – principles, concepts, and therapeutic use of stem cell therapy and tissue engineering in equine medicine.
The Canadian veterinary journal = La revue veterinaire canadienne    May 5, 2009   Volume 50, Issue 2 155-165 
Koch TG, Berg LC, Betts DH.This paper provides a bird's-eye perspective of the general principles of stem-cell therapy and tissue engineering; it relates comparative knowledge in this area to the current and future status of equine regenerative medicine.The understanding of equine stem cell biology, biofactors, and scaffolds, and their potential therapeutic use in horses are rudimentary at present. Mesenchymal stem cell isolation has been proclaimed from several equine tissues in the past few years. Based on the criteria of the International Society for Cellular Therapy, most of these cells are more correctly referred t...
Horse bone marrow mesenchymal stem cells express embryo stem cell markers and show the ability for tenogenic differentiation by in vitro exposure to BMP-12.
BMC cell biology    April 22, 2009   Volume 10 29 doi: 10.1186/1471-2121-10-29
Violini S, Ramelli P, Pisani LF, Gorni C, Mariani P.Mesenchymal stem cells (MSCs) have been recently investigated for their potential use in regenerative medicine. MSCs, in particular, have great potential, as in various reports they have shown pluripotency for differentiating into many different cell types. However, the ability of MSCs to differentiate into tendon cells in vitro has not been fully investigated. Results: In this study, we show that equine bone marrow mesenchymal stem cells (BM-MSCs), defined by their expression of markers such as Oct4, Sox-2 and Nanog, have the capability to differentiate in tenocytes. These differentiated cell...
Development of a mechanically stable support for the osteoinductive biomaterial COLLOSS E.
Journal of tissue engineering and regenerative medicine    December 4, 2008   Volume 3, Issue 2 149-152 doi: 10.1002/term.138
Lode A, Bernhardt A, Kroonen K, Springer M, Briest A, Gelinsky M.The application of bone graft substitutes with osteoinductive properties is of high importance for the repair of large bone defects. COLLOSS E, a protein lyophilizate extracted from equine long bones, exhibits an osteoinductive potential which has been proven in several studies. In this work, a mechanically stable, but biodegradable support for COLLOSS E has been developed aiming at a bone graft substitute that retains shape and size when coming in contact with body fluids. Mineralization of collagen type I, isolated from horse tendon, resulted in a stable collagen hydroxyapatite nanocomposite...
Regenerative medicine for tendinous and ligamentous injuries of sport horses.
The Veterinary clinics of North America. Equine practice    March 4, 2008   Volume 24, Issue 1 191-201 doi: 10.1016/j.cveq.2007.11.002
Fortier LA, Smith RK.After tendon injury, the scar tissue that replaces the damaged tendon results in a substantial risk for reinjury. The goal of regenerative therapies is to restore normal structural architecture and biomechanical function to an injured tissue. Successful restoration processes for any tissue are thought to recapitulate those of development, in which there are spatial and temporal interactions between scaffold, growth factors, and cell populations.
Equine umbilical cord blood contains a population of stem cells that express Oct4 and differentiate into mesodermal and endodermal cell types.
Journal of cellular physiology    October 12, 2007   Volume 215, Issue 2 329-336 doi: 10.1002/jcp.21312
Reed SA, Johnson SE.Mesenchymal stem cells (MSCs) offer promise as therapeutic aids in the repair of tendon, ligament, and bone damage suffered by sport horses. The objective of the study was to identify and characterize stem-like cells from newborn foal umbilical cord blood (UCB). UCB was collected and MSC isolated using human reagents. The cells exhibit a fibroblast-like morphology and express the stem cell markers Oct4, SSEA-1, Tra1-60 and Tra1-81. Culture of the cells in tissue-specific differentiation media leads to the formation of cell types characteristic of mesodermal and endodermal origins. Chondrogenic...
VetCell Bioscience Ltd–regenerative medicine for the world of animal health.
Regenerative medicine    May 1, 2007   Volume 1, Issue 3 393-396 doi: 10.2217/17460751.1.3.393
Mountford D.VetCell Bioscience is a UK-based company focused on pioneering the use of regenerative medicine in the animal health market. VetCell was formed in partnership with the Royal Veterinary College and the Institute for Orthopaedic and Musculoskeletal Science to develop the use of cellular therapies to treat athletic injuries in horses. This ground-breaking work has been the springboard from which the Company has expanded into other areas of veterinary regenerative medicine.
Harnessing the stem cell for the treatment of tendon injuries: heralding a new dawn?
British journal of sports medicine    August 25, 2005   Volume 39, Issue 9 582-584 doi: 10.1136/bjsm.2005.015834
Smith RK, Webbon PM.No abstract available
A new collagen biomatrix of equine origin versus a cadaveric dura graft for the repair of dural defects–a comparative animal experimental study.
Acta neurochirurgica    June 3, 2005   Volume 147, Issue 8 877-887 doi: 10.1007/s00701-005-0552-0
Knopp U, Christmann F, Reusche E, Sepehrnia A.Numerous types of materials have been evaluated over the past decades in the quest for the ideal dural replacement, but no product fully meets all the applicable criteria. This paper presents the long-term results of an animal trial of a collagen biomatrix (TISSUDURA, Baxter AG, Vienna/Austria) for the repair and regeneration of dural defects. This product provides a matrix with a special layer structure and consists of pure naturally cross-linked collagen of equine origin. The comparable material is Tutoplast Dura, a human cadaveric-derived dural graft preserved in a multiple stage chemical p...